Wyeth Pharmaceuticals : Premarin, Prempro and hormone replacement therapy (A) / Kathryn I. C. Huang, Megan E. Vanaelstyn, James S. O'Rourke.

Format:

Book

Author/Creator:

Huang, Kathryn I. C., author.

Vanaelstyn, Megan E., author.

O'Rourke, James S., IV, 1946- author.

Series:

SAGE Knowledge. Cases.

SAGE Knowledge. Cases

Language:

English

Subjects (All):

Wyeth (Firm).

Pharmaceutical industry--United States.

Pharmaceutical industry.

Menopause--Hormone therapy.

United States.

Menopause--Hormone therapy--United States.

Menopause.

Women's Health Initiative (U.S.).

Physical Description:

1 online resource : illustrations.

Place of Publication:

London : SAGE Publications Ltd, 2017.

System Details:

text file

Summary:

Millions of women worldwide between the ages of 45 and 55 experience the effects of menopause and have sought both treatment and relief in the form of hormone replacement therapy. Wyeth Pharmaceuticals, a division of Wyeth, Inc., is the market leader in prescription drug treatment for menopause with Premarin, a blend of natural estrogens (for women who have had a hysterectomy), and Prempro, a one-tablet hormone replacement therapy consisting of natural estrogens plus progestin. A stunning set of results from the Womens Health Initiative, released in the summer of 2002, however, challenges conventional approaches to treatment and poses a significant threat to Wyeth share price and market leadership.

Notes:

Originally published: Huang, K. I. C., Vanaelstyn, M. E., & ORourke, J. S. (2003). Wyeth Pharmaceuticals: Premarin, Prempro and hormone replacement therapy (A). 03-05(A). Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.

No ILL or scholarly sharing allowed.

Description based on XML content.

ISBN:

9781526406521

OCLC:

1017714005

Access Restriction:

Restricted for use by site license.